Literature DB >> 22539661

A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.

Danuta M Skowronski1, Naveed Z Janjua, Gaston De Serres, Anne-Luise Winter, James A Dickinson, Jennifer L Gardy, Jonathan Gubbay, Kevin Fonseca, Hugues Charest, Natasha S Crowcroft, Monique Douville Fradet, Nathalie Bastien, Yan Li, Mel Krajden, Suzana Sabaiduc, Martin Petric.   

Abstract

BACKGROUND: During the 2010-2011 winter, a large number of outbreaks due to influenza A/H3N2 at long-term care facilities, including higher-than-expected attack rates among vaccinated staff, were reported in some regions of Canada. Interim analysis from the community-based sentinel surveillance system showed circulating H3N2 variants and suboptimal vaccine effectiveness (VE), assessed here for the entire season's data set.
METHODS: Nasal/nasopharyngeal swabs and epidemiologic details were collected from patients presenting to sentinel sites within 7 days of onset of influenza-like illness. Cases tested positive for influenza by real-time reverse-transcription polymerase chain reaction; controls tested negative. Odds ratios for medically attended, laboratory-confirmed influenza in vaccinated vs nonvaccinated participants were used to derive adjusted VE. Viruses were characterized by hemagglutination inhibition (HI), and the hemagglutinin genes of a subset were sequenced to explore vaccine relatedness.
RESULTS: Final 2010-2011 VE analysis included 1718 participants (half aged 20-49 years), 93 with A(H1N1)pdm09, 408 with A/H3N2, and 199 with influenza B. Among adults aged 20-49 years, adjusted VE was 65% (95% confidence interval [CI], 8%-87%) for A(H1N1)pdm09 and 66% (95% CI, 10%-87%) for influenza B. Vaccine effectiveness was substantially lower for A/H3N2, at 39% (95% CI, 0%-63%). Phylogenetic analysis identified 2 circulating H3N2 variant clades, A/HongKong/2121/2010 (87%) and A/Victoria/208/2009 (11%), bearing multiple amino acid substitutions at antigenic sites (12 and 8, respectively) compared with the H3N2 vaccine component used in Canada (A/Victoria/210/2009[NYMC X-187]). However, HI characterized all H3N2 isolates as well matched to the vaccine.
CONCLUSIONS: Public health observations of increased facility H3N2 outbreaks were consistent with the sentinel network's detection of genetic variants and suboptimal VE but not with conventional HI characterization. We highlight the utility of a multicomponent sentinel surveillance platform that incorporates genotypic, phenotypic, and epidemiologic indicators into the assessment of influenza virus, new variant circulation, vaccine relatedness, and VE.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22539661     DOI: 10.1093/cid/cis431

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  49 in total

1.  Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates.

Authors:  Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto
Journal:  Clin Infect Dis       Date:  2013-11-13       Impact factor: 9.079

Review 2.  Influenza vaccine failure: failure to protect or failure to understand?

Authors:  Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2018-06-26       Impact factor: 5.217

3.  Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility.

Authors:  Suzanne E Ohmit; Joshua G Petrie; Ryan E Malosh; Alicia M Fry; Mark G Thompson; Arnold S Monto
Journal:  J Infect Dis       Date:  2014-11-21       Impact factor: 5.226

4.  Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015.

Authors:  Danuta M Skowronski; Catharine Chambers; Gaston De Serres; Suzana Sabaiduc; Anne-Luise Winter; James A Dickinson; Jonathan B Gubbay; Kevin Fonseca; Steven J Drews; Hugues Charest; Christine Martineau; Mel Krajden; Martin Petric; Nathalie Bastien; Yan Li; Derek J Smith
Journal:  J Infect Dis       Date:  2017-04-01       Impact factor: 5.226

Review 5.  Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Authors:  Andrea Orsi; Filippo Ansaldi; Daniela de Florentiis; Antonella Ceravolo; Valentina Parodi; Paola Canepa; Martina Coppelli; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

6.  Reply to Sullivan and Kelly and Skowronski et al.

Authors:  Arnold S Monto; Suzanne E Ohmit
Journal:  Clin Infect Dis       Date:  2013-04-25       Impact factor: 9.079

7.  Influenza vaccine effectiveness by test-negative design - Comparison of inpatient and outpatient settings.

Authors:  Shuo Feng; Benjamin J Cowling; Sheena G Sullivan
Journal:  Vaccine       Date:  2016-02-23       Impact factor: 3.641

8.  Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population.

Authors:  Joshua G Petrie; Emily T Martin; Rachel Truscon; Emileigh Johnson; Caroline K Cheng; E J McSpadden; Ryan E Malosh; Adam S Lauring; Lois E Lamerato; Maryna C Eichelberger; Jill M Ferdinands; Arnold S Monto
Journal:  Vaccine       Date:  2019-02-07       Impact factor: 3.641

9.  Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine.

Authors:  Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia
Journal:  JAMA Netw Open       Date:  2018-10-05

10.  Influenza Vaccine Effectiveness in Preventing Hospitalizations in Older Patients With Chronic Obstructive Pulmonary Disease.

Authors:  Andrea S Gershon; Hannah Chung; Joan Porter; Michael A Campitelli; Sarah A Buchan; Kevin L Schwartz; Natasha S Crowcroft; Aaron Campigotto; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; J Dayre McNally; David C Richardson; Susan E Richardson; Laura C Rosella; Andrew E Simor; Marek Smieja; George Zahariadis; Jeffrey C Kwong
Journal:  J Infect Dis       Date:  2020-01-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.